Monocytes Derived From Human Pluripotent Stem Cells Engineered for Detection of Pyrogens.

Area of Science:

• Biotechnology
• Cell Biology
• Immunology

Background:

• Parenteral drug safety relies on detecting pyrogens like endotoxins and non-endotoxins.
• Traditional methods, Rabbit Pyrogen Test (RPT) and Limulus Amebocyte Lysate (LAL) assay, are animal-based with limitations.
• The Monocyte Activation Test (MAT) is promising but operationally complex and requires significant human blood volume.

Purpose of the Study:

• To develop a rapid, consistent, and practical pyrogen detection method.
• To overcome the limitations of existing pyrogen testing methodologies.
• To establish an alternative to animal-derived and complex human blood-based assays.

Main Methods:

• Directed in vitro differentiation of human embryonic stem cells (hESCs) to generate monocytes (hESC-Mono).
• Integration of hESC-Mono with a luciferase reporter system for pyrogen detection.
• Validation of hESC-Mono for detecting lipopolysaccharide (LPS), lipoteichoic acid (LTA), and fungal Zymosan.

Main Results:

• hESC-Mono demonstrated batch-to-batch consistency and functional similarity to peripheral blood monocytes.
• The developed method showed sensitive reporting for multiple pyrogen types (LPS, LTA, Zymosan).
• hESC-Mono maintained stable expression of Toll-like receptors, crucial for pyrogen detection.

Conclusions:

• A novel, rapid pyrogen detection method using hESC-derived monocytes and a luciferase reporter system was successfully developed and validated.
• This method offers a stable, consistent, and potentially more practical alternative to traditional pyrogen testing.
• The use of hESC-Mono addresses limitations of current pyrogen detection assays, improving drug safety assessment.